Vaccine therapy in patients with renal cell carcinoma
/in Hypernephroma, International Publications, IOZK Veröffentlichungen /von 2009-01-30 / Eur. Urol. 2009 Jun;55(6):1333-42Newcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibrosis in mice
/in International Publications, Newcastle Disease Virus /von 2009-01-28 / Liver Int. 2009 Apr;29(4):593-602Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity
/in Dendritic Cells, International Publications /von 2009-01-26 / Clin. Dev. Immunol. 2008;2008:106321Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and class II antigens
/in Dendritic Cells, International Publications /von 2009-01-26 / Blood 2009 Apr;113(18):4213-23In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection
/in HIV/AIDS, International Publications /von 2009-01-23 / PLoS ONE 2009;4(1):e4256Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2009-01-20 / J. Dermatol. Sci. 2009 Apr;54(1):31-7Newcastle disease virus-induced cytopathic effect in infected cells is caused by apoptosis
/in International Publications, Newcastle Disease Virus /von 2009-01-17 / Virus Res. 2009 Apr;141(1):13-20Regulation of heat-induced apoptosis by Mcl-1 degradation and its inhibition by Hsp70
/in Hyperthermia, International Publications /von 2009-01-16 / Cell Death Differ. 2009 Apr;16(4):638-47Hyperthermia-treated mesenchymal stem cells exert antitumor effects on human carcinoma cell line
/in Hyperthermia, International Publications /von 2009-01-15 / Cancer 2009 Jan;115(2):311-23
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution